Your email has been successfully added to our mailing list.

×
0.0150450450450451 0.0150450450450451 0.0150450450450451 0.0150450450450451 0.0150150150150151 -0.018018018018018 -3.003003002996E-05 -0.00900900900900895
Stock impact report

BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation

BioXcel Therapeutics, Inc (BTAI)  More Company Research Source: GlobeNewswire
Last bioxcel therapeutics, inc earnings: 11/14 07:00 am Check Earnings Report
PDF Data read-out expected in 1H 19 Results expected to support dose selection for anticipated registration trials in 2019 NEW HAVEN, Conn., Dec. 19, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that the first six subjects have been dosed in the Company’s Phase 1 pharmacokinetic (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex). BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. The IND-opening Phase 1 study is a placebo-controlled, single dose, dose-escalation study of BXCL501 that is expected to enroll up to 60 healthy adult volunteers across various dosing groups. The primary endpoints are pharmacokinetics and safety, with secondary endpoints including assessment of pharmacodynamics (PD) and the relationship betwee [Read more]
Impact snapshot Event time: BTAI
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
BTAI alerts
from News Quantified
Opt-in for
BTAI alerts

from News Quantified
Opt-in for
BTAI alerts

from News Quantified